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Abstract 
Aims: To assess continuous glucose monitoring (CGM) derived intra-day glucose profiles 
using global guideline for type 2 diabetes recommended by the International Diabetes 
Federation (IDF). 
Methods: The Cochrane Library, MEDLINE, PubMed, CINAHL and Science Direct were 
searched to identify observational studies reporting intra-day glucose profiles using CGM in 
people with type 2 diabetes on any anti-diabetes agents. Overall and subgroup analyses were 
conducted to summarise mean differences between reported glucose profiles (fasting glucose, 
pre-meal glucose, postprandial glucose and post-meal glucose spike/excursion) and the IDF 
targets.   
Results: Twelve observational studies totalling 731 people were included. Pooled fasting 
glucose (0.81 mmol/L, 95% CI, 0.53–1.09 mmol/L), postprandial glucose after breakfast 
(1.63 mmol/L, 95% CI, 0.79–2.48 mmol/L) and post-breakfast glucose spike (1.05 mmol/L, 
95% CI, 0.13–1.96 mmol/L) were significantly higher than the IDF targets. Pre-lunch 
glucose, pre-dinner glucose and postprandial glucose after lunch and dinner were above the 
IDF targets but not significantly. Subgroup analysis showed significantly higher fasting 
glucose and postprandial glucose after breakfast in all groups: HbA1c <7% and ≥7% (53 
mmol/mol) and duration of diabetes <10 years and ≥10 years. 
Conclusions: Independent of HbA1c, fasting glucose and postprandial glucose after breakfast 
are not well-controlled in type 2 diabetes.  
Word count: 200/200 
Keywords: Continuous glucose monitoring, Glucose, Glucose profiles, Type 2 diabetes 
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1. Introduction 
One of the main therapeutic goals of type 2 diabetes management is to achieve and maintain 
glucose within target range and to prevent diabetes related complications [1]. The clinical 
gold standard for assessing glycaemic control is currently HbA1c [2]. A target HbA1c 
(glycated haemoglobin) of <7% (53 mmol/mol) is recommended for people with type 2 
diabetes to reduce the risk of developing complications [1]. However, HbA1c provides only 
an average assessment of glycaemic control [3], and intra-day glucose profiles: fasting 
glucose, pre-meal glucose and postprandial glucose; need to be well-controlled as these 
glucose profiles impact on HbA1c [4]. Recently the introduction of continuous glucose 
monitoring (CGM) technology enables detailed and accurate assessment of glucose profiles 
throughout the day [5]. The International Diabetes Federation (IDF) have produced evidence-
based global guideline for type 2 diabetes which recommend targets of fasting or pre-meal 
glucose ≤6.5 mmol/L and postprandial glucose ≤9 mmol/L respectively to achieve 
recommended HbA1c <7% (53 mmol/mol) [1]. The aim of this meta-analysis is to pool 
evidence from observational studies using CGM to ascertain if glucose profiles are well-
controlled within the IDF range throughout the day in type 2 diabetes. 
2. Material and methods 
2.1. Protocol and registration 
A protocol for this review and meta-analysis was developed and is available from 
PROSPERO (PROSPERO 2016: CRD42016049207). 
2.2. Search strategy 
The Cochrane Library, MEDLINE, PubMed, CINAHL and Science Direct databases were 
searched for literature published in English until March 2018. The following three main 
search terms and their synonyms were used: (I) type 2 diabetes and its synonyms (e.g. non-
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insulin dependent diabetes mellitus and adult onset diabetes); (II) continuous glucose 
monitoring (CGM) and its synonyms (e.g. CGM and real-time CGM) and (III) glucose and its 
synonyms (e.g. glycaemic variability and postprandial glucose). 
2.3. Selection of studies and eligibility criteria 
In this systematic review and meta-analysis, studies investigating fasting glucose, pre-meal 
glucose and postprandial glucose using CGM in people with type 2 diabetes until March 2018 
were included. The study designs eligible for this review were different types of 
observational studies (e.g. cross-sectional study, case control study and prospective study) 
which included people with type 2 diabetes aged over 18 years. No restrictions were placed 
on types of CGM and whether participants took anti-diabetes agents or on the type of anti-
diabetes agents. Experimental studies (drug and exercise interventions), qualitative studies 
and any studies in people with type 1 diabetes, people with latent autoimmune diabetes in 
adults, people with gestational diabetes, pregnant people and critically ill people were 
excluded.  
Two reviewers (ACP and SFMC) carried out three phases to select studies. These two 
reviewers reviewed articles independently, but they discussed and decided together in case of 
doubt. In phase one, the titles of articles were screened, and the relevant articles were selected 
for phase two. In phase two abstracts were reviewed, and in phase three the full texts of the 
remaining articles were reviewed.  
2.4. Data extraction 
The information was extracted from the eligible articles on: (1) general information 
(including main author and the year of publication), (2) characteristics of studies (including 
study design and duration), (3) characteristics of sample (including age, sample size, 
medications and duration of type 2 diabetes) and (4) outcome measures (including fasting 
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glucose, pre-meal glucose, postprandial glucose and HbA1c). Two reviewers (ACP and 
SFMC) performed data extraction independently, and any discrepancies were resolved by 
discussion with the input of a third reviewer (AFK) where needed.  
2.5. Data synthesis and analysis 
For primary outcome measures, mean differences between CGM measured fasting glucose, 
pre-meal glucose and postprandial glucose and the IDF targets (Fasting glucose ≤6.5 mmol/L, 
Pre-meal glucose ≤6.5 mmol/L, Postprandial glucose ≤9 mmol/L) were meta-analysed using 
the inverse variance method. To evaluate postprandial glucose excursion, post-breakfast 
glucose spike, post-lunch glucose spike and post-dinner glucose spike were calculated by 
subtracting pre-meal glucose from post-meal glucose. Difference between the IDF targets for 
pre-meal glucose (6.5 mmol/L) and postprandial glucose (9 mmol/L) was defined as target 
post-meal glucose spike (≤2.5 mmol/L). Mean differences between post-breakfast glucose 
spike, post-lunch glucose spike and post-dinner glucose spike and the IDF target (≤2.5 
mmol/L) were also meta-analysed. The standard errors used in meta-analysis were calculated 
from standard deviations [6–14] and interquartile ranges [4] for each study [15–17]. The 
standard errors for the IDF target values were substituted with zero [18]. The I
2
 statistic was 
used to assess the heterogeneity between studies [19], and the random effects model was used 
for moderate to high heterogeneity [20,21]. To ascertain if glucose profiles are well-
controlled in people with below and above target HbA1c, we stratified the results for the 
following subgroups: HbA1c <7% (53 mmol/mol) and HbA1c ≥7% (53 mmol/mol). Finally, 
because diabetes duration can influence intra-day glucose profiles, we also stratified results 
for duration of diabetes <10 years and duration of diabetes ≥10 years. Statistical analyses 
were performed using the Cochrane Review Manager 5.3. The mean difference and 95% 
confidence interval (CI) are reported in meta-analysis, and P-value ≤0.05 was considered 
statistically significant. By assuming a Gaussian distribution between subjects, the 
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percentages of people with poor fasting glucose (>6.5 mmol/L), pre-meal glucose (>6.5 
mmol/L), postprandial glucose (>9 mmol/L) and HbA1c (≥7% or 53 mmol/mol) were also 
estimated.  
2.6. Quality assessment 
The quality of all studies was assessed using the QUALSYST checklist from “Standard 
Quality Assessment Criteria for Evaluating Primary Research Papers from a Variety of 
Fields” (Alberta Heritage Foundation for Medical Research) [22]. To interpret the quality of 
studies, an arbitrary quality score was set at 70% of the possible total score of 100%, and the 
study with score ≥70% was graded as high-quality. Two reviewers (ACP and SFMC) 
conducted the quality assessment of articles independently with discrepancies resolved 
through discussion.   
3. Results 
3.1. Literature search and study selection 
The primary searches identified 2745 articles via the Cochrane Library, MEDLINE, PubMed, 
CINAHL and Science Direct databases. After duplicates were removed, 1624 articles 
remained at the title and abstract review phases. After titles and abstracts were reviewed, 
1540 articles were excluded for the following reasons: irrelevant (n = 1353), type 1 or other 
diabetes (n = 95), pregnant people (n = 10), critically ill people (n = 45), qualitative study (n 
= 1), experimental studies (n = 26) and age under 18 years (n = 10). Full-text of 84 articles 
were reviewed using predefined inclusion and exclusion criteria, and 12 articles meeting the 
inclusion criteria were included in this systematic review and meta-analysis (Fig. 1).  
3.2. Study characteristics 
Twelve observational (eight cross-sectional, two longitudinal, one prospective and one 
retrospective) studies investigating fasting glucose, pre-meal glucose and postprandial 
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glucose by CGM were included. Participants with known type 2 diabetes for 1.7 years [4], 
4.6 years [11], 6.9 years [9], 7.3 years [12], 8.1 years [15], 11 years [7], 12.9 years [6] and 
14.7 years [10] were respectively used in eight studies. One study included newly diagnosed 
type 2 diabetes [8], and three studies did not report the sample’s duration of diabetes 
[13,14,16]. Characteristics and main findings of the studies are reported in Table 1.   
Five studies were performed in Europe (1 in Germany, 1 in the UK, 1 in the Netherlands, 1 in 
the UK and France and 1 in Denmark). Four studies were conducted in Asia (3 in Japan and 1 
in Taiwan), and one was from Australia and the remaining two were from Iran. The sample 
size and study duration ranged from n = 11 [15] to n = 248
 
[16] and 1 day [4,6] to 12 days 
[7], respectively. Total 731 people from twelve observational studies were included in this 
meta-analysis, and fasting glucose, pre-breakfast glucose, pre-dinner glucose, postprandial 
glucose after breakfast, postprandial glucose after lunch, postprandial glucose after dinner 
and HbA1c data were respectively obtained from 619, 410, 410, 645, 476, 476 and 731 
people. Participants were taking different anti-diabetes agents (metformin, sulphonylurea, 
thiazolidinedione, α-glucosidase inhibitor, dipeptidyl peptidase-4 inhibitor, glucagon-like 
peptide-1 receptor agonist, sodium-glucose cotransporter 2 inhibitor, glinides and insulin) [6–
13,15,16]. Participants with diet management were included in four studies [4,12,14,16].  
The study objectives stated were to evaluate glucose profiles [4–10,13,15,16] and 
associations of HbA1c with glucose profiles [11,12,14]. Fasting glucose (pre-breakfast 
glucose) in ten studies [4,7–11,13–16] and pre-lunch and pre-dinner glucose in four studies 
[4,8,11,16] were reported. Nine studies reported postprandial glucose after breakfast [4,6–
10,12,13,16], and seven studies reported postprandial glucose after lunch and dinner [4,6–
9,13,16]. Participants were asked to record time of meals in nine studies [7–13,15,16] and 
were instructed to consume meals at standardised time in two studies [4,6]. The glucose 
values before corresponding meals were regarded as fasting glucose (pre-breakfast glucose), 
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pre-lunch glucose and pre-dinner glucose [4,7–11,13–16]. Postprandial glucose was defined 
as average 2 h glucose [6,7,9,13] and peak glucose after meal [4,8,10,12,16]. All studies 
measured and reported HbA1c using laboratory analyses.  
3.3. Quality of studies  
The majority of studies had high quality scores, ranging from 70% [9] to 94% [8,12]. All 
studies sufficiently expressed study designs and methods, but with no clear information of 
participants’ medications in one study [6]. 
3.4. Accuracy of CGM used in studies 
Accuracy of CGM was determined by mean absolute relative difference (MARD). Medtronic 
CGMS system Gold (2
nd
 generation) or Medtronic MiniMed CGM in nine studies 
[4,6,7,9,11–14,16], Medtronic iPro2 CGM in three studies [8,10,11] and GlucoDay S CGM 
in one study [15] were used, and their MARD values were 11%-20.6%, 9.9% and 15%, 
respectively [13,23–27]. 
3.5. Overall analyses of glucose profiles 
Poor fasting glucose, pre-lunch glucose, pre-dinner glucose, postprandial glucose after 
breakfast, postprandial glucose after lunch, postprandial glucose after dinner and HbA1c 
control were observed in 100%, 92.7%, 32.2%, 96.7%, 72.3%, 72.3% and 67.0% of people, 
respectively. Fig. 2A-C show the meta-analysis forest plots of mean differences in fasting 
glucose, pre-lunch glucose and pre-dinner glucose compared with the IDF target. Fasting 
glucose was significantly higher than the IDF target (0.81 mmol/L, 95% CI, 0.53–1.09 
mmol/L, P < 0.00001). But, there were no significant differences between pre-lunch glucose 
(0.21 mmol/L, 95% CI, -0.06–0.49 mmol/L, P = 0.12) and pre-dinner glucose (0.24 mmol/L, 
95% CI, -0.40 to 0.87 mmol/L, P = 0.47) and the IDF target.  
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Mean differences between postprandial glucose after meals and post-meal glucose spikes and 
the IDF targets are described in Fig. 3A-F. Compared with the IDF target, postprandial 
glucose after breakfast was significantly higher (1.63 mmol/L, 95% CI, 0.79–2.48 mmol/L, P 
= 0.0002). However, postprandial glucose after lunch (0.38 mmol/L, 95% CI, -0.33–1.08 
mmol/L, P = 0.29) and dinner (0.45 mmol/L, 95% CI, -0.37–1.26 mmol/L, P = 0.28) were not 
significantly different from the IDF target. Post-breakfast glucose spike (1.05 mmol/L, 95% 
CI, 0.13–1.96 mmol/L, P = 0.02) was significantly higher than the IDF target but not post-
lunch glucose spike (0.35 mmol/L, 95% CI, -0.62–1.32 mmol/L, P = 0.48) and post-dinner 
glucose spike (0.80 mmol/L, 95% CI, -0.29–1.88 mmol/L, P = 0.15). 
3.6. Subgroup analyses of glucose profiles 
Subgroup analyses of glucose profiles show that fasting glucose was significantly higher than 
the IDF target in both HbA1c <7% (53 mmol/mol) (0.68 mmol/L, 95% CI, 0.39–0.97 
mmol/L, P < 0.00001) and HbA1c ≥7% groups (53 mmol/mol) (0.94 mmol/L, 95% CI, 0.37–
1.50 mmol/L, P = 0.001) (Table 2). Moreover, significantly high postprandial glucose after 
breakfast was observed in both HbA1c <7% (53 mmol/mol) (0.67 mmol/L, 95% CI, 0.13–
1.20 mmol/L, P = 0.01) and HbA1c ≥7% groups (53 mmol/mol) (2.79 mmol/L, 95% CI, 
1.88–3.70 mmol/L, P < 0.00001). Post-breakfast glucose spike was significantly higher than 
the IDF target in HbA1c ≥7% group (2.29 mmol/L, 95% CI, 1.40–3.18 mmol/L, P < 
0.00001), but there were no significant differences between the remaining glucose profiles 
and the IDF targets in both groups.  
Both groups with duration of diabetes <10 years (1.06 mmol/L, 95% CI, 0.39–1.72 mmol/L, 
P = 0.002) (1.37 mmol/L, 95% CI, 0.50–2.23 mmol/L, P = 0.002) and duration of diabetes 
≥10 years (0.80 mmol/L, 95% CI, 0.45–1.15 mmol/L, P < 0.00001) (2.22 mmol/L, 95% CI, 
0.41–4.03 mmol/L, P = 0.02) had significantly higher fasting glucose and postprandial 
glucose after breakfast compared with the IDF targets (Table 2). There was significantly high 
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post-breakfast glucose spike in group with duration of diabetes <10 years (1.26 mmol/L, 95% 
CI, 0.15–2.38 mmol/L, P = 0.03) but not in group with duration of diabetes ≥10 years (1.04 
mmol/L, 95% CI, -2.68–4.77 mmol/L, P = 0.58) compared with the IDF target. Both post-
lunch glucose spike and post-dinner glucose spike in group with duration of diabetes <10 
years were not significantly different from the IDF target. Differences between pre-lunch 
glucose, pre-dinner glucose, postprandial glucose after lunch and postprandial glucose after 
dinner and the IDF targets were not significant in both groups.  
4. Discussion 
CGM technology enables continuous accurate monitoring of intra-day glucose profiles. To 
our knowledge, this is the first systematic review and meta-analysis that synthesise new 
knowledge about intra-day glucose profiles acquired by this technology and assessed using 
the IDF targets. We found that people with type 2 diabetes do not achieve the IDF targets for 
fasting glucose, postprandial glucose after breakfast and post-breakfast glucose spike with 
diet management and anti-diabetes agents. Pre-lunch glucose, pre-dinner glucose, 
postprandial glucose after lunch, postprandial glucose after dinner, post-lunch glucose spike 
and post-dinner glucose spike are marginally higher than the IDF targets but not statistically 
significant.  
Subgroup analyses revealed that this poor control of fasting glucose and postprandial glucose 
after breakfast was independent of HbA1c and duration of diabetes, because even people with 
HbA1c <7% (53 mmol/mol) and duration of diabetes <10 years experienced poor glucose 
control before and after breakfast. It appears that postprandial glucose after breakfast was 
higher in people with HbA1c ≥7% (53 mmol/mol) and duration of diabetes ≥10 years than 
those with HbA1c <7% (53 mmol/mol) and duration of diabetes <10 years, and this is in 
agreement with previous epidemiological evidence [4,28]. Postprandial glucose after lunch, 
  
11 
 
postprandial glucose after dinner and post-breakfast glucose spike seems to achieve the IDF 
targets in people with HbA1c <7% (53 mmol/mol), but all glucose profiles were above the 
targets in people with HbA1c ≥7% (53 mmol/mol) and duration of diabetes <10 years and 
≥10 years.  
There is strong observational evidence that fasting glucose is associated with vascular events 
and mortality, and HbA1c level is consistently influenced by fasting glucose or pre-breakfast 
glucose and pre-lunch glucose but not with pre-dinner glucose [4,8,14,29,30,31,32]. High 
postprandial glucose after breakfast and lunch can also predict the cardiovascular events in 
type 2 diabetes, and this effect is independent and stronger than fasting glucose and HbA1c 
[33,34]. In general, the association of HbA1c with postprandial glucose was well established 
[4,35,36] but not with postprandial glucose after each meal in a day. A study identified a 
higher correlation of HbA1c with postprandial glucose after breakfast than postprandial 
glucose after lunch and no effect of postprandial glucose after dinner in type 2 diabetes [8]. 
Although this evidence is limited, high glucose profiles after breakfast seems to be clinically 
important. The finding from this meta-analysis suggests that people with type 2 diabetes with 
HbA1c <7% (53 mmol/mol) or ≥7% (53 mmol/mol) are very likely to have high fasting 
glucose and postprandial glucose after breakfast, and this might be clinically useful to 
improve diabetes management.  
An important point of this review is that there is the need for the improvement of current 
diabetes management, and other adjunct therapy should be added. One potential therapeutic 
target is to modify lifestyle factors, in particular, sedentary/sitting time, leading to high 
glucose profiles in people with type 2 diabetes. The negative impact of daily sedentary/sitting 
time and the beneficial effect of interruption of sedentary/sitting time on fasting glucose and 
postprandial glucose were observed in recent cross-sectional studies [37–39]. However, these 
studies only looked at the association of sedentary pattern and periodic venous glucose before 
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and after a test meal rather than continuous glucose profiles throughout the day in free-living 
settings. Future studies are therefore needed to evaluate the impact of daily sedentary 
behaviour, physical activity pattern and other lifestyle factors on intra-day glucose profiles 
using CGM.  
There are several strengths of this meta-analysis. First, the quality scores of the included 
studies are relatively high. Second, subgroup analysis used in this meta-analysis allowed us to 
evaluate glucose profiles for HbA1c <7% (53 mmol/mol), HbA1c ≥7% (53 mmol/mol), 
duration of diabetes <10 years and duration of diabetes ≥10 years. Third, the use of CGM in 
the included studies allowed us to analyse and evaluate the full picture of glucose profiles 
throughout the day. Finally, the IDF guideline used in the present meta-analysis is evidence-
based and specific for type 2 diabetes, and 36% of national guidelines used globally were 
based on the IDF guideline [40]. 
This meta-analysis also has some limitations. First, the sample size was relatively small in 
most of the studies included in this meta-analysis, and this tends to be the case in CGM based 
studies due to the relatively high cost of CGM. Second, there might be study selection bias 
because the majority of studies included in this meta-analysis are cross-sectional and the 
availability of other study designs are limited. Third, the reliability of pooled glucose profiles 
might be limited by the heterogeneity between studies, and this may result from variability in 
study designs, methodologies, participants and anti-diabetes agents between studies. 
Nonetheless, the random effects model allowing the study outcomes to vary in a normal 
distribution between studies was used to conduct analyses [41]. Fourth, some important 
glucose control measures, such as glycaemic variability and bedtime glucose, were not 
reported in this meta-analysis, and these glucose control measures should be evaluated in 
future studies. Fifth, CGM used in the studies were much outdated, and insights into glucose 
profiles were limited because their monitoring duration (e.g. GlucoDay S CGM monitors 
  
13 
 
glucose for 2 days) was relatively short compared to current CGM systems (e.g. FreeStyle 
Libre CGM monitors glucose for 14 days). Finally, the use of different CGM with different 
MARD values in the included studies might influence pooled glucose profiles and might 
contribute to the observed heterogeneity.  
In conclusion, fasting glucose and postprandial glucose after breakfast do not achieve the IDF 
targets in type 2 diabetes even with currently prescribed diet management, anti-diabetes 
agents and HbA1c <7% (53 mmol/mol). People with type 2 diabetes are therefore at risk of 
diabetes complications, and adjunct therapy such as lifestyle modifications should be 
promoted. The impact of lifestyle factors on intra-day glucose profiles using current CGM 
should be explored in future studies.  
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Author (year) Study 
design 
Study 
duration 
(days) 
Sample 
size 
Age 
(years) 
Medications Fasting 
glucose 
(mmol/L) 
PPG after 
breakfast 
(mmol/L) 
Pre-lunch 
glucose 
(mmol/L) 
PPG after 
lunch 
(mmol/L) 
Pre-dinner 
glucose 
(mmol/L) 
PPG after 
dinner 
(mmol/L) 
HbA1c 
(%)  
HbA1c 
(mmol/mol) 
Ando et al. (2013) 
[4] 
Cross- 
sectional 
1 30 42-66  Diet 6.9 ± 0.3 11.9 ± 0.7 6.5 ± 0.3 11.7 ± 0.7 6.4 ± 0.4 12.4 ± 0.8 7.7 ± 0.2 
 
61 ± 1.2 
Cichosz et al. (2013) 
[8] 
Cross- 
sectional 
3 86 61 ± 1.1 Met 6.9 ± 0.1 10.2 ± 0.3 6.6 ± 0.1 8.4 ± 0.2 6.6 ± 0.2 8.8 ± 0.2 6.5 ± 0.1 
 
48 ± 0.4 
Monnier et al. (2013)  
[16] 
Cross- 
sectional 
3 248 59.9 ± 0.6 Met, SU, α-
GI, TZD, 
DPP-4 I, 
Diet 
6.9 ± 0.1 11.1 ± 0.2 6.6 ± 0.1 9.3 ± 0.1 6.3 ± 0.1 9.3 ± 0.1 7.2 ± 0.1 
 
55 ± 0.6 
Hay et al. (2003) [7] Longitu-
dinal 
12 25 73.9 ± 0.9 Met, SU 7.7 ± 0.4 9.3 ± 0.6  8.7 ± 0.6  8.2 ± 0.5 6.2 ± 0.2 44 ± 1.2 
Bonakdaran and 
Khajeh-Dalouie 
(2011)  [9] 
Longitu-
dinal 
6 17 42.4 ± 2.1 Met, SU 
 
 
7.7 ± 0.4 10.7 ± 0.8  9.9 ± 0.5  9.5 ± 0.7 6.3 ± 0.4 
 
45 ± 2.5 
Yano et al. (2013)  
[6] 
Cross- 
sectional 
1 49 67.3 ± 1.5 ADA  11.6 ± 0.5  11.1 ± 0.7  11.6 ± 0.5 8.7 ± 0.2 72 ± 1.2 
McGeoch et al. 
(2012)  [14] 
Cross- 
sectional 
3 29               62 ± 1.1 Diet 7.3 ± 0.2      6.7 ± 0.1 
 
50 ± 1.2 
Praet et al. (2006)  
[15] 
Cross- 
sectional   
2 11             58 ± 1 Met, SU 8.6 ± 0.6      7.4 ± 0.3 57 ± 1.9 
Takeishi et al. (2016) 
[10] 
Retrosp-
ective 
4 106 66.6 ± 1.1 Met, SU, α-
GI, TZD, 
DPP-4 I, 
GLP-1 RA, 
Rapid acting 
insulin 
secretagogue
, SGLT2 I, 
Insulin 
7.2 ± 0.2 12.6 ± 0.3     8.7 ± 0.1 71 ± 1.5 
Lin et al. (2016) [11] Cross-
sectional 
3 46 54.2 ± 1.5 Met 8.1 ± 0.2  7.5 ± 0.3  7.6 ± 0.2  7.5 ± 0.1 58 ± 0.1 
Kohnert et al. (2007) 
[12] 
Prospect
-ive 
4 63 62.9 ± 1.1 Diet, Met, 
SU, Insulin 
 9.5 ± 0.2     6.1 ± 0.1 43 ± 0.4 
Bonakdaran and 
Rajabian (2009) [13] 
Cross-
sectional 
3 21 51.9 ± 2.1 Met, SU, 
Meglitinides 
  7 ± 0.2 8.7 ± 0.6  7.9 ± 0.3  7.5 ± 0.3 6.7 ± 0.1 
 
50 ± 0.6 
Abbreviation: Met, metformin; SU, sulphonylurea; α-GI, α-glucosidase inhibitor; TZD, thiazolidinedione; DPP-4 I, dipeptidyl peptidase-4 inhibitor; 
GLP-1 RA, Glucagon-like peptide-1 receptor agonist; SGLT2 I, Sodium-glucose cotransporter 2 inhibitor; ADA, anti-diabetes agents.                                                        
            
Table 1 – Characteristics of the included studies. 
Tables 
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Subgroups Number 
of studies 
Heterogeneity test 
      I2         P-Value 
Model selected Mean difference P-Value 
HbA1c <7% (53 mmol/mol) 
   Fasting glucose (mmol/L) 
   Postprandial glucose after breakfast (mmol/L) 
   Postprandial glucose after lunch (mmol/L) 
   Postprandial glucose after dinner (mmol/L) 
 
5 
5 
4 
5 
 
     56%     0.06 
     53%     0.08 
     75%     0.007 
     81%     0.001 
 
Random 
Random 
Random 
Random 
 
0.68 (0.39–0.97) 
0.67 (0.13–1.20) 
-0.37 (-1.08–0.33) 
-0.59 (-1.41–0.24) 
 
<0.00001 
0.01 
0.30 
0.16 
   Post-breakfast glucose spike (mmol/L) 4      67%     0.03 Random -0.02 (-1.03–0.98) 0.96 
HbA1c ≥7% (53 mmol/mol) 
   Fasting glucose (mmol/L) 
   Pre-lunch glucose (mmol/L) 
   Pre-dinner glucose (mmol/L) 
   Postprandial glucose after breakfast (mmol/L) 
   Postprandial glucose after lunch (mmol/L) 
   Postprandial glucose after dinner (mmol/L) 
5 
3 
3 
4 
3 
3 
     89%     <0.00001 
     76%     0.01 
     94%     <0.00001 
     83%     0.0005 
     89%     0.0001 
     94%     <0.00001 
Random 
Random 
Random 
Random 
Random 
Random 
0.94 (0.37–1.50) 
0.33 (-0.20–0.87) 
0.28 (-0.67–1.23) 
2.79 (1.88–3.70) 
1.60 (-0.11–3.31) 
2.01 (-0.05–4.07) 
0.001 
0.23 
0.57 
<0.00001 
0.07 
0.06 
   Post-breakfast glucose spike (mmol/L) 3      74%     0.02 Random 2.29 (1.40–3.18) <0.00001 
   Post-lunch glucose spike (mmol/L) 2      90%     0.002 Random 1.32 (-1.11–3.76) 0.29 
   Post-dinner glucose spike (mmol/L) 2      91%     0.0009 Random 1.87 (-1.06–4.79) 0.21 
Duration of diabetes <10 years 
   Fasting glucose (mmol/L) 
   Pre-lunch glucose (mmol/L) 
   Pre-dinner glucose (mmol/L) 
   Postprandial glucose after breakfast (mmol/L) 
   Postprandial glucose after lunch (mmol/L) 
   Postprandial glucose after dinner (mmol/L) 
 
5 
3 
3 
4 
3 
3 
 
     89%     <0.00001 
     72%     0.01 
     87%     0.0005 
     79%     0.003 
     92%     <0.00001 
     90%     <0.0001 
 
Random 
Random 
Random 
Random 
Random 
Random 
 
1.06 (0.39–1.72) 
0.33 (-0.20–0.87) 
0.40 (-0.37–1.18) 
1.37 (0.50–2.23) 
0.90 (-0.92–2.73) 
1.13 (-0.85–3.10) 
 
0.002 
0.23 
0.31 
0.002 
0.33 
0.26 
   Post-breakfast glucose spike (mmol/L) 3      62%     0.07 Random 1.26 (0.15–2.38) 0.03 
   Post-lunch glucose spike (mmol/L) 2      94%     <0.0001 Random 0.91 (-2.42–4.24) 0.59 
   Post-dinner glucose spike (mmol/L) 2      94%     <0.0001 Random 1.51 (-2.21–5.22) 0.43 
Duration of diabetes ≥10 years 
   Fasting glucose (mmol/L) 
   Postprandial glucose after breakfast (mmol/L) 
   Postprandial glucose after lunch (mmol/L) 
   Postprandial glucose after dinner (mmol/L) 
 
2 
3 
2 
2 
 
     20%     0.26 
     92%     <0.00001 
     85%     0.009 
     96%     <0.00001 
 
Fixed 
Random 
Random 
Random 
 
0.80 (0.45–1.15) 
2.22 (0.41–4.03) 
0.87 (-1.48–3.22) 
0.90 (-2.43–4.23) 
 
<0.00001 
0.02 
0.47 
0.60 
   Post-breakfast glucose spike (mmol/L) 2      95%     <0.00001 Random 1.04 (-2.68–4.77) 0.58 
Dara are presented as mean difference (95% CI) 
Table 2 – Mean difference between fasting glucose, pre-meal glucose and postprandial glucose and the IDF targets (Fasting glucose ≤6.5 mmol/L, Pre-meal glucose 
≤6.5 mmol/L, Postprandial glucose ≤9 mmol/L, Post-meal glucose spike ≤2.5 mmol/L): a subgroup analysis. 
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Figure Captions 
Fig. 1 – PRISMA diagram of the study selection process.  
Fig. 2 – Forest plots of mean differences between (A) fasting glucose, (B) pre-lunch 
glucose and (C) pre-dinner glucose and the IDF targets (Fasting glucose ≤6.5 mmol/L, 
Pre-meal glucose ≤6.5 mmol/L): an overall analysis. Abbreviation: SE, standard error. 
 
Fig. 3 – Forest plots of mean differences between (A) postprandial glucose after 
breakfast, (B) postprandial glucose after lunch, (C) postprandial glucose after dinner, 
(D) post-breakfast glucose spike, (E) post-lunch glucose spike and (F) post-dinner 
glucose spike and the IDF targets (Postprandial glucose ≤9 mmol/L, Post-meal glucose 
spike ≤2.5 mmol/L): an overall analysis. Abbreviation: PPG, postprandial glucose; SE, 
standard error. 
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